TriSalus Life Sciences, Inc.
closedU=S+W/3W=S@11.50
TLSI
Capital Structure & Economics
Trust Size$200,000,000
Unit Price$11.50
Warrant Coverage1/3
Sponsor Promote20%
Implied Equity Architecture
Capital Allocation Baseline
Trust (100.0%)
Implied Dilution Drag
33% Warrant Inclusion| Public Trust Allocation | $200,000,000 |
| Sponsor At-Risk Capital | N/A |
| Total Underwriting Discount | N/A |
| Trust Per Unit (Implied) | $11.50 |
| Sponsor Promote Allocation | 20% |
Deal Lifecycle
IPO PricedNov 30, 2020
Target AnnouncedAug 12, 2021
Maturation Wall
Dec 22, 2022
Announced Target / M&A
- Target CompanyDynavax Technologies Corporation
- Sectorbiotechnology
- Announced Deal Size$220,000,000
- Announcement Date2021-08-12
Board & Officers
- Mary SzelaCEO
- Christopher C. DeweyOfficer
- Officer
- Director
- Director
- Director
Advanced Structuring Terms
| Target Sectors | biotechnology |
Syndicate & Advisors
Interactive Deal Modeling
Base financial constraints (Trust Size, Warrants, Promote) are pre-loaded into the calculation engines. Proceed to model implied dilution and advisory friction limits.